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ABSTRACT  
Tyrosine Kinase Inhibitors are new drugs developed in the last decade. For Non-Small Cell Lung Cancer this drug brought more hope for 
patients with this disease. Also TKIs are better tolerated then chemotherapy. The efficacy of TKIs is dependent of the presence of Epidermal 
Grows Factor Receptor gene mutation. This mutation account for about 9% of patients with lung cancer in Europe. This short re view try to give 
the minimal knowledge to clinicians, especially medical oncologists, about mechanism of action, pharmacokinetics of TKIs used in the treatment 
NSCLC. 
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Non-small cell lung cancer (NSCLC) causes the highest 
cancer mortality in the world. In 2018, there were 2 million 
new cases worldwide. In the first 3 places regarding the 
incidence of NSCLC in the world in 2018 were: Hungary 56.7 
/ 100,000, Serbia 49.8 / 100,000 and New Caledonia 
(France) 42.3 / 100,000. In Romania, the mortality due to 
lung cancer was 37.7 / 100,000 in 2017.1 One of the 
therapeutic advances in this true scourge, represented by 
NSCLC, is tyrosine kinase inhibitors (TKIs). 
Tyrosine kinases are enzymes responsible for so-called 
cascade activation of many proteins through signal 
transduction. Proteins are activated by phosphorylation, a 
step that TKIs inhibit. TKIs are commonly used in cancer 
therapy.2 
Prior to the introduction of TKIs in NSCLC therapy, platinum 
salt combination chemotherapy resulted in overall survival 
(OS) for many patients with NSCLC less than one year.3 With 
the introduction of EGFR inhibitors represented by TKIs, the 
therapeutic approach of NSCLC has changed by taking into 
account when establishing the therapeutic conduct of both 
histology and genetic determinations appearing in so-called 
"targeted therapies".4 
The chemical formulas of the main TKIs are presented below 
5:
  
                    
1. Erlotinib (First generation TKIs)         2. Osimertinib (Thread generation TKIs       3. Afatinib (Second generation TKIs) 
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The mechanism of molecular action 
EGFR, also called ErbB1, is part of the ErB family. There are 4 
receptors described as tyrosine kinase receptors. Other 
members of this receptor family include ErbB2 (HER2), 
ErbB3 (HER3) and ErbB4 (HER4). The structure of these 
receptors is the commune that comprises an extracellular 
ligand binding domain, a transmembrane domain and an 
intracellular domain that has tyrosine kinase activity for 
signal transduction. Binding of its ligand to EGFR initiates an 
intracellular signaling cascade that ultimately leads to cell 
proliferation and results in cell survival6. 
All EGFR-TKI have a similar high affinity for the EGFR 
receptor 7-9 Afatinib and dacomitinib also have a high affinity 
for the HER2 and HER4 receptors. Afatinib also inhibits 
HER3 transphosphorylation, thereby blocking the signaling 
of all members of the ErbB family.10 In vitro, all tyrosine 
kinase inhibitors cause inhibition of proliferation of NSCLC 
cell lines expressing L858R EGFR or L858R / T790M EGFR 
mutations, with lower activity against wild-type EGFR 
lines.11 
Pharmacokinetics 
As this review is addressed to clinicians, we will discuss only 
a few practical aspects of TKIs pharmacokinetics used in 
advanced NSCLC. 
From the point of view of the administration of these drugs, 
the researchers pointed out that Gefitinib could be taken 
without regard to food intake, because bioavailability is not 
influenced by food. In contrast, food intake concomitantly 
with Dasatinib and Erlotinib increases bioavailability. For the 
mentioned TKIs, the primary enzyme in their metabolism is 
CYP3A4. The major metabolites of  
Dasatinib are 4 (BMS-582691), M5 (BMS-606181), M6 (BMS-
573188), for erlotinib is NorErlotinib (OSI-420) and for 
Gefitinib NorGefitinib (M523595).12 
Oral absorption of EGFR TKIs is slow to moderate and has 
significant variability both within the same individual and 
from one individual to another. Plasma concentrations of 
gefitinib are obtained 3–7 hours after administration to 
healthy subjects and patients with solid tumors.13 The 
solubility of these compounds at high pH is limited [14] and 
in this case co-administration of drugs that increase gastric 
pH, such as histamine H2 receptor antagonists and proton 
pump inhibitors may lead to decreased absorption and 
bioavailability. Similar effects may have high doses of short-
acting antacids if taken regularly around the time of taking 
gefitinib.14 Erlotinib has absorption characteristics similar to 
those of gefitinib. However, as food increases bioavailability 
(from 60% to almost 100%), erlotinib should be given at 
least one hour before or two hours after eating.15 Afatinib 
reaches peak plasma concentrations 2–5 hours after oral 
administration in patients with solid tumors. The absolute 
bioavailability of afatinib is not known. 16 . Foods have a 
moderate influence on the absorption of afatinib, and 
therefore patients should take afatinib at least 1 h before or 
2-3 hours after meal. 
It has been established that Dacomitinib has a good oral 
bioavailability (80%) after a dose of 45 mg and its 
concentration after administration behaves after linear 
kinetics after single or multiple doses.17-18 Foods have only a 
slight, negligible effect (data for dacomitinib indicate that 
food intake has no effect on bioavailability) on absorption, 
but co-administration with antacid medication should be 
avoided. For the other EGFR TKIs, interindividual variability 
is high (coefficient of variation up to 50%).19 In summary, 
gefitinib, erlotinib, afatinib and dacomitinib demonstrate 
significant interindividual variability in drug uptake. 
The distribution of EGFR TKIs is characterized by an 
extensive tissue distribution and moderate binding of plasma 
proteins to the sea, ranging from 90% for gefitinib to 97–
98% for dacomitinib, dacomitinib is excreted as both a 
parent compound and metabolites..20-21 The half-life is 
generally extended (2-3 days) in patients with cancer but for 
erlotinib (36 h) 22 and afatinib (37 h) the half-life is shorter.24 
Metabolism is slightly different, so unlike afatinib, gefitinib, 
erlotinib, dacomitinib undergoes extensive hepatic 
metabolism predominantly by cytochrome P450 (CYP) 
dependent enzymes. Gefitinib is metabolised by CYP3A4 and, 
to a lesser extent, by CYP2D6 and CYP3A5.25,26 Erlotinib is 
metabolized by CYP3A4 / 3A5 and, to a lesser extent, by 
CYP1A1 / 1A2 isoenzymes, to the active metabolite 
desmethyl erlotinib, which subsequently enter into an 
oxidation and glucuronidation process. Extra-hepatic 
metabolism is achieved by CYP3A4 in the intestine, CYP1A1 
in the lung and in tumor tissue where CYP1B1 also 
contributes to metabolic elimination of erlotinib. It is known 
that cigarette smoking induces CYP enzymes which is a key 
enzyme. Currently studies have shown that induction of 
CYP1A1 / 1A2 in smokers results in increased metabolism 
and clearance of erlotinib which subsequently leads to a 
reduction in exposure after a standard therapeutic 
dose.27,28,29  
Dacomitinib is metabolized by oxidation process and 
conjugation with glutathione involving CYP2D6 and CYP3A4, 
resulting in the active metabolite O-des methyl dacomitinib 
having in vitro activity similar to the parent compound.30 In 
contrast, afatinib undergoes minimal biotransformation, and 
CYP-mediated oxidant metabolism is negligible.31 
Osimertinib, a third-generation tyrosine kinase (TKI) 
inhibitor, undergoes significant hepatic elimination. No 
apparent differences in the safety of osimertinib 
administration were found between patients with normal 
liver function and those with mild or moderate hepatic 
impairment.32  
Administration of oral osimertinib once daily resulted in 
accumulation with steady state exposure after 15 days of 
administration. In the constant state, the ratio Cmax 
(maximum concentration) to Cmin (minimum concentration) 
was 1.6. After absorption, the mean time to Cmax of 
osimertinib was 6 hours (range 3-24 hours). The mean 
volume of distribution of osimertinib at steady state (Vss / F) 
was 918 L. The plasma protein binding of osimertinib was 
95%. E Osimertinib plasma concentrations decreased with 
elimination time and an estimated half-life of osimertinib 
was 48 hours and oral clearance (CL / F) was 14.3 (L / h). . 
The main in vitro metabolic pathways of osimertinib were 
oxidation (predominantly CYP3A) and dealkylation. Two 
pharmacologically active metabolites (AZ7550 and AZ5104) 
were identified in plasma after oral administration of 
osimertinib. Osimertinib is eliminated mainly in the faeces 
(68%) and in the urine to a lesser extent (14%).33 
Benefits of treatment with TKIs in NSCLC 
The first generation of EGFR TKIs, gefitinib and erlotinib, act 
by reversibly and competitively inhibiting the EGFR tyrosine 
kinase domain. Both gefitinib and erlotinib have shown in 
studies that have resulted in significant improvements in 
response rate, progression-free survival (PFS) and quality of 
life (QOL) compared with chemotherapy in the selected 
population of NSCLC patients with EGFR mutation (3-5). So 
far, it has not been shown in any of these studies that there is 
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a benefit in overall survival (OS). This may be due to cross-
over treatments and the relatively high efficacy of 
chemotherapy in this type of lung cancer. 
In addition, the toxicity was comparable for gefitinib and 
erlotinib. The difference from second-generation TKIs is that 
the latter, namely afatinib and dacomitinib, are irreversible 
covalent inhibitors of EGFR. 
Afatinib and dacomitinib also inhibited other members of the 
epidermal growth factor (HER) receptor family (pan-HER 
inhibitors). Consequently, both dacomitinib and afatinib also 
have a certain therapeutic value in NSCLC with driver 
mutation of HER2.34,35,36 The Lux-Lung Phase IIb study 7 was 
the first to compare a second-generation EGFR TKI (afatinib) 
with a first-generation EGFR TKI (gefitinib) in first-line 
treatment for NSCLC harboring an activating EGFR mutation . 
In this study, afatinib resulted in an improvement of 
statistically significant progression free survival and time-to-
treatment failure.37 
More recently, Wu et al published the results of the ARCHER 
1050 study, recently published in Lancet Oncol. It is a phase 
III study comparing dacomitinib versus gefitinib in the first 
line treatment. In this study, dacomitinib significantly 
improved PFS from 9.2 to 14.7 months (HR: 0.59 and P 
<0.0001) compared to gefitinib. Data on overal survival are 
immature. In this study, treatment with dacomitinib had an 
increased toxicity of grade ¾. Toxicity has often required 
dose reduction. Dacomitinib is thus the first EGFR TKI that 
has demonstrated statistically significant and clinically 
significant superior activity in PFS compared to gefitinib, a 
first-generation TKI. However, given the increased toxicity, 
more data will be needed on the clinical benefits and impact 
of dacomitinib treatment on quality of life.38 
Osimertinib is a third generation of TKIs that irreversibly 
blocks the EGFR receptor. This third generation TKI 
selectively inhibits both EGFR/ TKI sensitizing mutation and 
EGFR /T790M resistance mutations. This compound has a 
lower activity against the wild type EGFR and is in fact, in the 
United States, the standard first-line treatment for patients 
with locally advanced or metastatic NSCLC with an 
epidermal growth factor receptor (EGFR) mutation. The FDA 
decision was made after the publication of positive overall 
survival (OS) results from the Phase III FLAURA study. This 
study was a randomized, double-blind, multi-center study 
with osimertinib in first-line treatment for patients with 
locally advanced or metastatic NSCLC with EGFR 
mutations.39,40 
Conclusions 
In summary, the EGFR-TKIs offer a targeted therapeutic 
approach to the management of NSCLC. Review of the 
pharmacokinetics of gefitinib, erlotinib, afatinib , dacomitinib 
end osimertinib highlight differences in absorption and/or 
metabolism which influence their potential for drug–drug 
interactions, highly relevant in the setting of polymedicated 
cancer patients. In routine clinical practice, afatinib may offer 
a number of theoretical advantages, notably lack of CYP-
related interaction potential as well as with acid-reducing 
agents (H2-receptor antagonists, proton-pump inhibitors and 
antacids). 
The first line therapy, for NSCLC with EGFR mutation, is in 
the latest evidence in favor of osimertinib. However 
clinicians should evaluate the patient condition and co 
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